Arbutus Biopharma (ABUS) Non-Current Assets (2010 - 2026)

Arbutus Biopharma has disclosed Non-Current Assets across 17 years of filings, most recently posting $153000.0 for Q1 2026.

• Non-Current Assets for Q1 2026 came in at $153000.0, down 24.26% year-over-year; the trailing twelve-month figure through Mar 2026 was $731000.0 (down 96.96% YoY), and the FY2025 annual result was $162000.0, down 96.31% from the prior year.
• Non-Current Assets came in at $153000.0 for Q1 2026 at Arbutus Biopharma, down from $162000.0 in the prior quarter.
• In the past five years, Non-Current Assets ranged from a high of $64.2 million in Q1 2022 to a low of $148000.0 in Q2 2025.
• The 5-year median for Non-Current Assets is $12.4 million (2023), against an average of $20.8 million.
• Across the five-year window, Non-Current Assets jumped 621.19% in 2022 and sank 98.75% in 2025, its largest moves.
• Arbutus Biopharma's Non-Current Assets stood at $44.3 million in 2022, then tumbled by 72.06% to $12.4 million in 2023, then slumped by 64.51% to $4.4 million in 2024, then tumbled by 96.31% to $162000.0 in 2025, then decreased by 5.56% to $153000.0 in 2026.
• The last three Non-Current Assets figures came in at $153000.0 (Q1 2026), $162000.0 (Q4 2025), and $268000.0 (Q3 2025), per Business Quant data.